Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. (Nasdaq: COCP) on June 18, 2025, reporting events that occurred on June 17, 2025. The Company is incorporated in Delaware and operates as a biopharmaceutical entity.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance changes rather than financial performance.
Material Changes
On June 17, 2025, the Board of Directors approved an amendment to the Company's Amended and Restated Bylaws. The amendment modifies the quorum requirement for stockholder meetings. Under the new provision, one-third of the aggregate voting power of outstanding shares entitled to vote, represented in person or by proxy, shall constitute a quorum.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document strictly addresses the bylaw amendment and lists the associated exhibits.
Key Facts for Investor Verification
- The quorum requirement for stockholder meetings has been reduced to one-third of the aggregate voting power.
- The amendment was approved by the Board of Directors on June 17, 2025.
- The full text of the amendment is available as Exhibit 3.1 to this filing.
- No financial data or operational updates were disclosed in this specific report.